<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2015-10-28" updated="2019-12-02">
  <drugbank-id primary="true">DB09275</drugbank-id>
  <drugbank-id>DBSALT001961</drugbank-id>
  <name>Bismuth subcitrate potassium</name>
  <description>A bismuth compound used for peptic ulcer and gastro-oesophageal reflux disease (GORD).</description>
  <cas-number>880149-29-1</cas-number>
  <unii>BQE6KE1T4H</unii>
  <average-mass>780.654</average-mass>
  <monoisotopic-mass>779.79034</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A18784</ref-id>
        <pubmed-id>1957120</pubmed-id>
        <citation>Lee SP: The mode of action of colloidal bismuth subcitrate. Scand J Gastroenterol Suppl. 1991;185:1-6.</citation>
      </article>
      <article>
        <ref-id>A18795</ref-id>
        <pubmed-id>3053124</pubmed-id>
        <citation>Wagstaff AJ, Benfield P, Monk JP: Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Drugs. 1988 Aug;36(2):132-57.</citation>
      </article>
      <article>
        <ref-id>A18865</ref-id>
        <pubmed-id>10971684</pubmed-id>
        <citation>Phillips RH, Whitehead MW, Lacey S, Champion M, Thompson RP, Powell JJ: Solubility, absorption, and anti-Helicobacter pylori activity of bismuth subnitrate and colloidal bismuth subcitrate: In vitro data Do not predict In vivo efficacy. Helicobacter. 2000 Sep;5(3):176-82.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L381</ref-id>
        <title>FDA Label</title>
        <url>http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050786s012lbl.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>For the treatment of peptic ulcer and gastro-oesophageal reflux disease (GORD).&#13;
Treatment of inflammatory and erosive-ulcerous diseases of gastric and duodenal mucosa:  gastritis, ulcer disease of the stomach and duodenum, functional non-ulcerous dyspepsia, erosive duodenitis, post-operative inflammatory and erosive changes â€“ anastomositis, peptic ulcer of anastomosis</indication>
  <pharmacodynamics>Bismuth subcitrate  is very effective in the treatment of gastroduodenal disorders and appears to act via several mechanisms. It has little acid-neutralizing effect and does not affect acid secretion.</pharmacodynamics>
  <mechanism-of-action>Colloidal bismuth subcitrate is very effective in the treatment of gastroduodenal disorders and appears to act via several mechanisms. It has little acid-neutralizing effect and does not affect acid secretion. It is uncertain whether it affects pepsin secretion, but it does inhibit peptic activity. It causes an increase in mucus glycoprotein secretion and may also bind to the gastric mucus layer to act as a diffusion barrier to HCl. It accelerates ulcer healing and causes an accumulation of epidermal growth factor around the ulcer. In addition, it has a cytoprotective effect and increases mucosal secretion of prostaglandins and bicarbonate. It has bactericidal effects against Helicobacter pylori (which is associated with gastritis and peptic ulcers). It also prevents adhesion of H. pylori to epithelial cells and can inhibit enzymes secreted by H. pylori, such as proteases, lipases, glycosidases, and phospholipases.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption>The mean peak whole-blood bismuth level after ingestion of colloidal bismuth subcitrate (214 mg bismuth) was more than 50 mg/liter and occurred at 30 minutes. After ingestion of bismuth subnitrate (205 mg bismuth), however, there was no evidence of bismuth absorption into blood, although in three of the volunteers who took bismuth subnitrate a week after colloidal bismuth subcitrate, baseline levels of blood bismuth were still elevated. Forty-five minutes after taking colloidal bismuth subcitrate, mean plasma levels for all five volunteers were also assessed and were 79.76 microg/liter as compared to blood levels of 47.6 microg/liter.</absorption>
  <half-life>The elimination half-life of bismuth is approximately 5 days</half-life>
  <protein-binding>&gt;90%</protein-binding>
  <route-of-elimination>Elimination of bismuth is primarily through urinary and biliary routes.</route-of-elimination>
  <volume-of-distribution/>
  <clearance>The rate of renal elimination appears to reach steady state 2 weeks after treatment discontinuation with similar rates of elimination at 6 weeks after discontinuation. The average urinary elimination of bismuth is 2.6% per day in the first two weeks after discontinuation (urine drug concentrations 24 to 250 mcg/mL) suggesting tissue accumulation and slow elimination. </clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as tricarboxylic acids and derivatives. These are carboxylic acids containing exactly three carboxyl groups.</description>
    <direct-parent>Tricarboxylic acids and derivatives</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic acids and derivatives</superclass>
    <class>Carboxylic acids and derivatives</class>
    <subclass>Tricarboxylic acids and derivatives</subclass>
    <alternative-parent>Alkoxides</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Carboxylic acid salts</alternative-parent>
    <alternative-parent>Carboxylic acids</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organic cations</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organic potassium salts</alternative-parent>
    <substituent>Aliphatic acyclic compound</substituent>
    <substituent>Alkoxide</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxylic acid</substituent>
    <substituent>Carboxylic acid salt</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Organic alkali metal salt</substituent>
    <substituent>Organic cation</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organic potassium salt</substituent>
    <substituent>Organic salt</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Tricarboxylic acid or derivatives</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001280</drugbank-id>
      <name>Bismuth subcitrate potassium monohydrate</name>
      <unii>R3O80H60KX</unii>
      <cas-number/>
      <inchikey>VBVVJMZCAZRTKA-UHFFFAOYSA-H</inchikey>
      <average-mass>834.699</average-mass>
      <monoisotopic-mass>833.82203</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">Bismuth subcitrate potassium anhydrous</synonym>
  </synonyms>
  <products>
    <product>
      <name>Pylera</name>
      <labeller>Aptalis Pharma Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246962</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pylera</name>
      <labeller>Axcan Pharma US, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>58914-600</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-05-01</started-marketing-on>
      <ended-marketing-on>2011-06-14</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA050786</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pylera</name>
      <labeller>Allergan, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>58914-601</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA050786</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pylera</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6151</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA050786</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Pylera</name>
      <ingredients>Bismuth subcitrate potassium + Metronidazole + Tetracycline</ingredients>
    </mixture>
    <mixture>
      <name>Pylera</name>
      <ingredients>Bismuth subcitrate potassium + Metronidazole + Tetracycline</ingredients>
    </mixture>
    <mixture>
      <name>Pylera</name>
      <ingredients>Bismuth subcitrate potassium + Metronidazole + Tetracycline</ingredients>
    </mixture>
    <mixture>
      <name>Pylera</name>
      <ingredients>Bismuth subcitrate potassium + Metronidazole + Tetracycline</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Bismuth containing drugs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Neurotoxic agents</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents>
    <patent>
      <number>6350468</number>
      <country>United States</country>
      <approved>2002-02-26</approved>
      <expires>2018-12-14</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00254</drugbank-id>
      <name>Doxycycline</name>
      <description>The serum concentration of Doxycycline can be decreased when it is combined with Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00256</drugbank-id>
      <name>Lymecycline</name>
      <description>The serum concentration of Lymecycline can be decreased when it is combined with Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00453</drugbank-id>
      <name>Clomocycline</name>
      <description>The serum concentration of Clomocycline can be decreased when it is combined with Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00560</drugbank-id>
      <name>Tigecycline</name>
      <description>The serum concentration of Tigecycline can be decreased when it is combined with Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00595</drugbank-id>
      <name>Oxytetracycline</name>
      <description>The serum concentration of Oxytetracycline can be decreased when it is combined with Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00618</drugbank-id>
      <name>Demeclocycline</name>
      <description>The serum concentration of Demeclocycline can be decreased when it is combined with Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00931</drugbank-id>
      <name>Metacycline</name>
      <description>The serum concentration of Metacycline can be decreased when it is combined with Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01017</drugbank-id>
      <name>Minocycline</name>
      <description>The serum concentration of Minocycline can be decreased when it is combined with Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01301</drugbank-id>
      <name>Rolitetracycline</name>
      <description>The serum concentration of Rolitetracycline can be decreased when it is combined with Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12035</drugbank-id>
      <name>Sarecycline</name>
      <description>The serum concentration of Sarecycline can be decreased when it is combined with Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12329</drugbank-id>
      <name>Eravacycline</name>
      <description>The serum concentration of Eravacycline can be decreased when it is combined with Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12455</drugbank-id>
      <name>Omadacycline</name>
      <description>The serum concentration of Omadacycline can be decreased when it is combined with Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13092</drugbank-id>
      <name>Meclocycline</name>
      <description>The serum concentration of Meclocycline can be decreased when it is combined with Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13264</drugbank-id>
      <name>Penimepicycline</name>
      <description>The serum concentration of Penimepicycline can be decreased when it is combined with Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01294</drugbank-id>
      <name>Bismuth subsalicylate</name>
      <description>Bismuth subsalicylate may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11281</drugbank-id>
      <name>Bismuth subcarbonate</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Bismuth subcarbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13209</drugbank-id>
      <name>Bismuth subnitrate</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Bismuth subnitrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13909</drugbank-id>
      <name>Bismuth subgallate</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Bismuth subgallate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13910</drugbank-id>
      <name>Valproate bismuth</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Valproate bismuth.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>Cyclosporine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00202</drugbank-id>
      <name>Succinylcholine</name>
      <description>Succinylcholine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>Reserpine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>Ziprasidone may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00260</drugbank-id>
      <name>Cycloserine</name>
      <description>Cycloserine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>Amitriptyline may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>Protriptyline may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00361</drugbank-id>
      <name>Vinorelbine</name>
      <description>Vinorelbine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>Clozapine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00372</drugbank-id>
      <name>Thiethylperazine</name>
      <description>Thiethylperazine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00391</drugbank-id>
      <name>Sulpiride</name>
      <description>Sulpiride may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00408</drugbank-id>
      <name>Loxapine</name>
      <description>Loxapine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00409</drugbank-id>
      <name>Remoxipride</name>
      <description>Remoxipride may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>Promazine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00433</drugbank-id>
      <name>Prochlorperazine</name>
      <description>Prochlorperazine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00444</drugbank-id>
      <name>Teniposide</name>
      <description>Teniposide may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00450</drugbank-id>
      <name>Droperidol</name>
      <description>Droperidol may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>Imipramine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>Chlorpromazine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>Haloperidol may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>Triflupromazine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>Cyclophosphamide may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>Nortriptyline may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>Vincristine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>Amoxapine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00623</drugbank-id>
      <name>Fluphenazine</name>
      <description>Fluphenazine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00649</drugbank-id>
      <name>Stavudine</name>
      <description>Stavudine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00679</drugbank-id>
      <name>Thioridazine</name>
      <description>Thioridazine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00680</drugbank-id>
      <name>Moricizine</name>
      <description>Moricizine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>Trimipramine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>Risperidone may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>Trifluoperazine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00850</drugbank-id>
      <name>Perphenazine</name>
      <description>Perphenazine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>Flupentixol may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>Ethanol may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00900</drugbank-id>
      <name>Didanosine</name>
      <description>Didanosine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00924</drugbank-id>
      <name>Cyclobenzaprine</name>
      <description>Cyclobenzaprine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00933</drugbank-id>
      <name>Mesoridazine</name>
      <description>Mesoridazine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01063</drugbank-id>
      <name>Acetophenazine</name>
      <description>Acetophenazine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>Promethazine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>Pimozide may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>Doxepin may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>Desipramine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01190</drugbank-id>
      <name>Clindamycin</name>
      <description>Clindamycin may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01199</drugbank-id>
      <name>Tubocurarine</name>
      <description>Tubocurarine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>Paclitaxel may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>Aripiprazole may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01239</drugbank-id>
      <name>Chlorprothixene</name>
      <description>Chlorprothixene may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>Clomipramine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01245</drugbank-id>
      <name>Decamethonium</name>
      <description>Decamethonium may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01246</drugbank-id>
      <name>Alimemazine</name>
      <description>Alimemazine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>Paliperidone may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium cation</name>
      <description>Lithium cation may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>Methotrimeprazine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01598</drugbank-id>
      <name>Imipenem</name>
      <description>Imipenem may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01608</drugbank-id>
      <name>Periciazine</name>
      <description>Periciazine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01614</drugbank-id>
      <name>Acepromazine</name>
      <description>Acepromazine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01615</drugbank-id>
      <name>Aceprometazine</name>
      <description>Aceprometazine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01618</drugbank-id>
      <name>Molindone</name>
      <description>Molindone may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01621</drugbank-id>
      <name>Pipotiazine</name>
      <description>Pipotiazine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01622</drugbank-id>
      <name>Thioproperazine</name>
      <description>Thioproperazine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01623</drugbank-id>
      <name>Thiothixene</name>
      <description>Thiothixene may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01624</drugbank-id>
      <name>Zuclopenthixol</name>
      <description>Zuclopenthixol may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01627</drugbank-id>
      <name>Lincomycin</name>
      <description>Lincomycin may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04836</drugbank-id>
      <name>Amineptine</name>
      <description>Amineptine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04842</drugbank-id>
      <name>Fluspirilene</name>
      <description>Fluspirilene may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04872</drugbank-id>
      <name>Osanetant</name>
      <description>Osanetant may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04888</drugbank-id>
      <name>Bifeprunox</name>
      <description>Bifeprunox may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04946</drugbank-id>
      <name>Iloperidone</name>
      <description>Iloperidone may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05316</drugbank-id>
      <name>Pimavanserin</name>
      <description>Pimavanserin may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05687</drugbank-id>
      <name>BL-1020</name>
      <description>BL-1020 may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06016</drugbank-id>
      <name>Cariprazine</name>
      <description>Cariprazine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06144</drugbank-id>
      <name>Sertindole</name>
      <description>Sertindole may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>Asenapine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06288</drugbank-id>
      <name>Amisulpride</name>
      <description>Amisulpride may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08815</drugbank-id>
      <name>Lurasidone</name>
      <description>Lurasidone may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08922</drugbank-id>
      <name>Perospirone</name>
      <description>Perospirone may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08927</drugbank-id>
      <name>Amperozide</name>
      <description>Amperozide may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08996</drugbank-id>
      <name>Dimetacrine</name>
      <description>Dimetacrine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09000</drugbank-id>
      <name>Cyamemazine</name>
      <description>Cyamemazine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09016</drugbank-id>
      <name>Butriptyline</name>
      <description>Butriptyline may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09128</drugbank-id>
      <name>Brexpiprazole</name>
      <description>Brexpiprazole may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09154</drugbank-id>
      <name>Sodium citrate</name>
      <description>Sodium citrate may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>Dosulepin may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09223</drugbank-id>
      <name>Blonanserin</name>
      <description>Blonanserin may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09224</drugbank-id>
      <name>Melperone</name>
      <description>Melperone may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09225</drugbank-id>
      <name>Zotepine</name>
      <description>Zotepine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09226</drugbank-id>
      <name>RP-5063</name>
      <description>RP-5063 may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09241</drugbank-id>
      <name>Methylene blue</name>
      <description>Methylene blue may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09286</drugbank-id>
      <name>Pipamperone</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Pipamperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Tianeptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09307</drugbank-id>
      <name>Oxaprotiline</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Oxaprotiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11376</drugbank-id>
      <name>Azaperone</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Azaperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11537</drugbank-id>
      <name>Pirlimycin</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Pirlimycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11540</drugbank-id>
      <name>Propiopromazine</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Propiopromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12093</drugbank-id>
      <name>Tetrahydropalmatine</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Tetrahydropalmatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12273</drugbank-id>
      <name>Ecopipam</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Ecopipam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12401</drugbank-id>
      <name>Bromperidol</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Bromperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12518</drugbank-id>
      <name>Raclopride</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Raclopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12693</drugbank-id>
      <name>Ritanserin</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Ritanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12710</drugbank-id>
      <name>Perazine</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Perazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12867</drugbank-id>
      <name>Benperidol</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Benperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12930</drugbank-id>
      <name>Opipramol</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Opipramol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12958</drugbank-id>
      <name>Prothipendyl</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Prothipendyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13025</drugbank-id>
      <name>Tiapride</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13114</drugbank-id>
      <name>Amitriptylinoxide</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Amitriptylinoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13213</drugbank-id>
      <name>Butaperazine</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Butaperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13225</drugbank-id>
      <name>Dibenzepin</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Dibenzepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13246</drugbank-id>
      <name>Quinupramine</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Quinupramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13256</drugbank-id>
      <name>Clothiapine</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Clothiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13273</drugbank-id>
      <name>Sultopride</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Sultopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13382</drugbank-id>
      <name>Chlorproethazine</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Chlorproethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13384</drugbank-id>
      <name>Melitracen</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Melitracen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13403</drugbank-id>
      <name>Oxypertine</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Oxypertine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13411</drugbank-id>
      <name>Lofepramine</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Lofepramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13420</drugbank-id>
      <name>Thiazinam</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Thiazinam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13496</drugbank-id>
      <name>Iprindole</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Iprindole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13523</drugbank-id>
      <name>Veralipride</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Veralipride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13552</drugbank-id>
      <name>Trifluperidol</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Trifluperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13554</drugbank-id>
      <name>Moperone</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Moperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13557</drugbank-id>
      <name>Thiopropazate</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Thiopropazate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13584</drugbank-id>
      <name>Gallamine</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Gallamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13598</drugbank-id>
      <name>Diethyl ether</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Diethyl ether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13665</drugbank-id>
      <name>Fluanisone</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Fluanisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13676</drugbank-id>
      <name>Mosapramine</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Mosapramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13782</drugbank-id>
      <name>Imipramine oxide</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Imipramine oxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13784</drugbank-id>
      <name>Dixyrazine</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Dixyrazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13791</drugbank-id>
      <name>Penfluridol</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Penfluridol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13841</drugbank-id>
      <name>Clopenthixol</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Clopenthixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14185</drugbank-id>
      <name>Aripiprazole lauroxil</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Aripiprazole lauroxil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14651</drugbank-id>
      <name>Perphenazine enanthate</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Perphenazine enanthate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00781</drugbank-id>
      <name>Polymyxin B</name>
      <description>Bismuth subcitrate potassium may increase the neurotoxic activities of Polymyxin B.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>0.79</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-1.6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.38e+01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-1.3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>bismuth(3+) pentapotassium bis(2-oxidopropane-1,2,3-tricarboxylate)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>bismuth(3+) pentapotassium bis(2-oxidopropane-1,2,3-tricarboxylate)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>780.654</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>779.79034</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[K+].[K+].[K+].[K+].[K+].[Bi+3].[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O.[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C12H8BiK5O14</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/2C6H7O7.Bi.5K/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;;;;/h2*1-2H2,(H,7,8)(H,9,10)(H,11,12);;;;;;/q2*-1;+3;5*+1/p-6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>YDDTTXDPCSCLKY-UHFFFAOYSA-H</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>143.45</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>78.69</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>13.97</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>10</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>3.05</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-4.2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7051</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>118987133</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347827831</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>34989447</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Bismuth_subcitrate</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0003089</id>
      <name>ATP-dependent Clp protease ATP-binding subunit ClpX</name>
      <organism>Helicobacter pylori (strain ATCC 700392 / 26695)</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A18784</ref-id>
            <pubmed-id>1957120</pubmed-id>
            <citation>Lee SP: The mode of action of colloidal bismuth subcitrate. Scand J Gastroenterol Suppl. 1991;185:1-6.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O25926" source="Swiss-Prot">
        <name>ATP-dependent Clp protease ATP-binding subunit ClpX</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>ATP-dependent specificity component of the Clp protease. It directs the protease to specific substrates. Can perform chaperone functions in the absence of ClpP.</specific-function>
        <gene-name>clpX</gene-name>
        <locus/>
        <cellular-location>Cytoplasmic</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.44</theoretical-pi>
        <molecular-weight>50352.815</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="85962">Helicobacter pylori (strain ATCC 700392 / 26695)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AE000511</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O25926</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CLPX_HELPY</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms/>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0012159|ATP-dependent Clp protease ATP-binding subunit ClpX
MNETLYCSFCKKPESRDPKKRRIIFASNLNKDVCVCEYCIDVMHGELHKYDNSLLALKRD
RLRRMESSAYEEEFLLSYIPAPKELKAVLDNYVIGQEQAKKVFSVAVYNHYKRLSFKEKL
KKQDNQDSNVELEHLEEVELSKSNILLIGPTGSGKTLMAQTLAKHLDIPIAISDATSLTE
AGYVGEDVENILTRLLQASDWNVQKAQKGIVFIDEIDKISRLSENRSITRDVSGEGVQQA
LLKIVEGSLVNIPPKGGRKHPEGNFIQIDTSDILFICAGAFDGLAEIIKKRTTQNVLGFT
QEKMSKKEQEAILHLVQTHDLVTYGLIPELIGRLPVLSTLDSISLEAMVDILQKPKNALI
KQYQQLFKMDEVDLIFEEEAIKEIAQLALERKTGARGLRAIIEDFCLDIMFDLPKLKGSE
VRITKDCVLKQAEPLIIAKTHSKILP</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012160|ATP-dependent Clp protease ATP-binding subunit ClpX (clpX)
ATGAACGAAACGCTTTATTGCAGTTTTTGCAAAAAACCAGAATCAAGAGATCCCAAAAAA
CGCCGCATTATTTTTGCGAGCAATCTCAATAAAGATGTGTGCGTGTGCGAATATTGTATA
GATGTGATGCATGGGGAATTGCACAAATACGACAATTCTTTATTGGCGCTCAAAAGAGAC
CGATTGAGAAGAATGGAATCTAGCGCTTATGAAGAAGAGTTTTTACTCTCTTACATTCCA
GCCCCTAAAGAGCTTAAGGCGGTTTTAGACAATTATGTGATAGGGCAAGAGCAGGCTAAA
AAGGTTTTTTCCGTAGCCGTGTATAACCATTACAAACGCTTATCTTTTAAAGAAAAACTC
AAAAAACAAGACAACCAAGACAGCAATGTGGAGTTAGAGCATTTAGAAGAAGTGGAGTTG
AGCAAGTCTAATATTTTACTAATCGGCCCTACAGGATCAGGCAAAACTTTAATGGCGCAA
ACTCTGGCCAAGCATTTGGATATTCCTATCGCCATTAGCGATGCGACTAGCTTGACTGAA
GCGGGCTATGTGGGCGAAGACGTGGAAAATATTCTCACAAGATTGTTGCAAGCGAGCGAC
TGGAATGTCCAAAAAGCCCAAAAAGGCATTGTGTTTATTGATGAGATTGATAAAATCAGC
CGTTTGTCAGAAAACCGCTCTATCACTAGAGATGTTTCTGGCGAGGGCGTTCAGCAAGCG
TTGTTGAAAATCGTTGAAGGTTCTTTAGTGAATATCCCCCCCAAAGGCGGCAGAAAGCAC
CCTGAGGGCAATTTCATTCAAATTGACACGAGCGATATTTTATTCATTTGTGCTGGAGCG
TTTGATGGGTTAGCTGAAATCATTAAAAAACGCACCACGCAGAATGTGTTGGGTTTCACT
CAAGAAAAGATGAGCAAAAAAGAGCAAGAAGCGATCTTGCATTTAGTCCAAACCCATGAC
CTGGTTACTTATGGGCTTATCCCTGAGCTTATTGGCCGTTTGCCGGTTTTAAGCACGCTA
GATAGCATCAGTTTAGAAGCGATGGTGGATATTTTACAAAAACCTAAAAACGCTCTTATC
AAGCAATACCAGCAGCTTTTCAAAATGGATGAGGTGGATTTGATCTTTGAAGAAGAAGCC
ATTAAAGAAATCGCTCAACTCGCATTAGAAAGAAAAACCGGGGCTAGGGGCTTAAGGGCG
ATCATTGAAGATTTTTGTTTGGATATTATGTTTGATTTACCCAAGCTTAAAGGATCGGAA
GTGCGTATCACTAAAGATTGTGTTTTAAAACAGGCTGAACCTTTGATCATTGCTAAAACG
CATTCTAAAATTCTTCCTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07724</identifier>
            <name>AAA_2</name>
          </pfam>
          <pfam>
            <identifier>PF10431</identifier>
            <name>ClpB_D2-small</name>
          </pfam>
          <pfam>
            <identifier>PF06689</identifier>
            <name>zf-C4_ClpX</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein folding</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>